

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092208 A3

(51) International Patent Classification⁷: **C07K 14/165**,
16/10, A61K 39/215

5V4 (CA). **PERREAULT, Helen** [CA/CA]; 631 Drake
Centre, Winnipeg, Manitoba R3T 5V4 (CA). **TYLER,**
Shaun [CA/CA]; 1015 rue Arlington Piece T2420, Win-
nipeg, Manitoba R3E 3P6 (CA).

(21) International Application Number:
PCT/CA2004/000558

(74) Agent: **ADE & COMPANY**; 1700-360 Main Street, Win-
nipeg, Manitoba R3C 3Z3 (CA).

(22) International Filing Date: 14 April 2004 (14.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/462,688 15 April 2003 (15.04.2003) US
60/472,416 22 May 2003 (22.05.2003) US

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicants (*for all designated States except US*): **HER
MAJESTY THE QUEEN IN RIGHT OF CANADA AS
REPRESENTED BY THE MINISTER OF HEALTH**
[CA/CA]; 1015 rue Arlington Piece T2420, Winnipeg,
Manitoba R3E 3P6 (CA). **UNIVERSITY OF MANI-
TOBA** [CA/CA]; 631 Drake Centre, Winnipeg, Manitoba
R3T 5V4 (CA).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JONES, Steven**
[CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg,
Manitoba R3E 3P6 (CA). **FELDMANN, Heinz** [CA/CA];
1015, rue Arlington pieceT2420, Winnipeg, Manitoba
R3E 3P6 (CA). **BASTIEN, Nathalie** [CA/CA]; 1015,
rue Arlington pieceT2420, Winnipeg, Manitoba R3E 3P6
(CA). **LI, Yan** [CA/CA]; 1015, rue Arlington pieceT2420,
Winnipeg, Manitoba R3E 3P6 (CA). **PLUMMER, Frank**
[CA/CA]; 1015, rue Arlington pieceT2420, Winnipeg,
Manitoba R3E 3P6 (CA). **ENS, Werner** [CA/CA]; 631
Drake Centre, Winnipeg, Manitoba R3T 5V4 (CA).
STANDING, Kenneth [CA/CA]; 631 Drake Centre,
Winnipeg, Manitoba R3T 5V4 (CA). **KROKHINE, Oleg**
[CA/CA]; 631 Drake Centre, Winnipeg, Manitoba R3T

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
20 January 2005

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: SARS-RELATED PROTEINS

(57) Abstract: Novel proteins isolated from a patient with SARS are described.

WO 2004/092208 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000558

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/165 C07K16/10 A61K39/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, Sequence Search, WPI Data, PAJ, BIOSIS, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DROSTEN CHRISTIAN ET AL: "Identification of a novel coronavirus in patients with severe acute respiratory syndrome." THE NEW ENGLAND JOURNAL OF MEDICINE. 15 MAY 2003, vol. 348, no. 20, 10 April 2003 (2003-04-10), pages 1967-1976, XP002305233 ISSN: 1533-4406 page 1971, left-hand column, paragraphs 1,2 figure 1</p> <p style="text-align: center;">----- -/--</p>	1-14

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

12 November 2004

Date of mailing of the international search report

26/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seroz, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA2004/000558

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>KSIAZEK T G ET AL: "A novel coronavirus associated with severe acute respiratory syndrome"</p> <p>NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 20, 10 April 2003 (2003-04-10), pages 1953-1966, XP002276003 ISSN: 1533-4406</p> <p>page 1955, right-hand column, last paragraph - page 1956, left-hand column, paragraph 1</p> <p>page 1958, left-hand column, last paragraph - page 1959, left-hand column, paragraph 1</p>	1-14
A	<p>POUTANEN S M ET AL: "Identification of severe acute respiratory syndrome in Canada"</p> <p>NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 348, no. 20, 31 March 2003 (2003-03-31), pages 1995-2005, XP002255633 ISSN: 0028-4793</p>	
P,X	<p>KROKHIN O ET AL: "MASS SPECTROMETRIC CHARACTERIZATION OF PROTEINS FROM THE SARS VIRUS"</p> <p>MOLECULAR AND CELLULAR PROTEOMICS, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 2, no. 5, May 2003 (2003-05), pages 346-356, XP001183239 ISSN: 1535-9476</p> <p>the whole document</p>	1-14
P,X	<p>MARRA M A ET AL: "The genome sequence of the SARS-associated coronavirus"</p> <p>SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399-1404, XP002269483 ISSN: 0036-8075</p> <p>page 1400, middle column, lines 10-13</p>	1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/000558

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15, 16
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 15, 16
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 10-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 15, 16

Present claims 15 and 16 relate to a compound defined by reference to a desirable characteristic or property, namely, the capability of binding to the claimed SARS-related proteins

The claims cover all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound/method/apparatus by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for said claims 15 and 16.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.